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Abstract
Background: It is well known that various polysaccharides present anti-tumour effects by inducing cell apoptosis and immunomodulation.
However, it is still unclear about the roles of polysaccharides isolated from Artemisia apiacea (HQG) to hepatoma and its underlying mechanism.
The objective of the study was to examine the anti-hepatoma effects of HQG and its related mechanism.
Materials and Methods: HQG was prepared in house and the quality and purity were confirmed by infra-red spectrum and gel permeation
chromatography (GPC). Tumour-bearing mice induced by injection of mouse hepatoma H22 cells were used to evaluate the tumour growth
inhibition by HQG administration. Cell immunostaining, JC1 staining and flow cytometer were performed to examine the cell apoptosis,
mitochondrial membrane potential change and immunomodulation in response to HQG treatment.
Results: HQG treatment inhibited hepatoma growth in tumour-bearing mice. Cell apoptosis rate of human hepatoma 7402 cells and of the cells
from ascites in tumour-bearing mice was increased after HQG treatment. Mitochondrial membrane potential in human hepatoma 7402 cells was
decreased after HQG treatment. CD4+ and CD8+ T- lymphocytes subpopulation was increased while the ratio of CD4+/ CD8+ decreased in
tumour-bearing mice after HQG administration. IFN-γ and IL-4 secretion was increased in spleen lymphocytes in tumour-bearing mice after HQG 
administration.
Conclusion: The study concluded that polysaccharides isolated from Artemisia apiacea (HQG) can inhibit hepatoma cell growths by facilitating
cell apoptosis and immuno-defence.
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Introduction
Cancer is always one of the leading death causes with high morbidity and mortality in human history. With the advancement of
understanding to tumorigenesis, in the past five decades, the conventional medical treatments to cancers including chemotherapy radiotherapy,
and surgery significantly improved the survival of patients with malignant cancers. Nevertheless, the overall therapeutic outcomes are still far
from satisfactory (Mushiake et al., 2005), since more and more evidences show that the current approaches to cancer therapy have severe side
effects, even adverse effects, such as the disruption of the body’s natural defence (Andrews et al., 2012; Chabner et al., 2005). Therefore, new
strategies to cancer treatment are being developed to combat the disease. Among them, immunotherapeutic is viewed as the most promising
approach against cancer (Borghaei et al., 2009).
Recently, plant-derived polysaccharides have been paid more and more attention due to their anti-cancer activities and their capability to
improve the body’s immunomodulation (Yoon et al., 2003; Nergard et al., 2004; Nam et al., 2009; Du et al., 2012). In oriental medicine, there has
been a long history of herbal use to prevent and treat diseases, including cancers, by modulating the body’s natural immune-defence system. It
was revealed that, among those herbs, polysaccharides are the major active ingredients exerting therapeutic efficacy. For example,
polysaccharides extracted from Sparassis crispa (Harada et al., 2002), Platycodon grandiflorum (Yoon et al., 2003), Vernonia kotschyana
(Nergard et al., 2004), Asterina pectinifera (Kim,et al., 2012) and more have been demonstrated to possess anti-cancer activities.
Polysaccharides isolated from Artemisia apiacea (HQG) are commonly used active extracts. Initial investigations indicated that HQG may
also play significant roles in anti-cancer activities. However, the underlying mechanism is poorly understood. In this study, we firstly isolated
HQG and then characterised the polysaccharides in the hepatoma cells and cancer-bearing mice model. Our results indicated that HQG exerts
anti-hepatoma activity by inducing cell apoptosis and promoting immunomodulation.
Materials and Methods
Preparation, purification and concentration measurement of HQG
The isolation and purification of crude polysaccharide were described previously (Cao et al., 2010). Briefly, the 4.0 kg of powdered
Artemisia apiacea (Youyang, Chongqing, China) were extracted three times with ethanol at 80℃ for 3 h. The residues were decocted three times
with water at 100℃ for 3h. After 3000 x g centrifugation for 10 min, the aqueous extract was concentrated at 60℃ in vacuum and treated with
three volumes of ethanol for precipitation at 4℃ overnight. The gel-like precipitate was suspended in water and dialysed against distilled water
(exclusion limit 3.5 kD). The non-dialyzable portion was frozen at -20℃, then thawed and centrifuged again to remove insoluble materials. After
the freeze-thaw process was repeated ten times, the supernatant was lyophilised and the crude polysaccharides fraction was obtained. The crude
polysaccharides (4%) was dissolved in distilled water and loaded onto a DEAE-Sephadex A-25 column (90 cm×5 cm). The column was
successively eluted with distilled water, 0.3 M and 0.5 M NaCl each time until the disappearance in elute of positive reaction for carbohydrate by
the phenol–sulphuric acid method. The 0.5 M NaCl-eluted fraction was collected, dialysed, lyophilised. The fraction containing carbohydrate was
pooled, dialysed, lyophilised, and further applied onto the column of Sephadex G-100(100 cm×3.5 cm) to get purified polysaccharides. The key
fraction was concentrated, dialysed and lyophilised.
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The molecular weights of the polysaccharides were determined by gel permeation chromatography (GPC) using a Waters 515 gel permeation
chromatography equipped with a TOSOH BIOSEP TSK-Gel G4000SWXL (7.8x300mm，Japan ) column. The columns were eluted with 0.1M
nitric acid and calibrated with standard Dextran (Sigma, St. Louis, MO, USA). The elution was monitored by Waters Alliance 2410 RI detector
(Waters, Milford, MA, USA).
The carbohydrate was quantified by the phenol–sulphuric acid method, using d-glucose as the standard. Protein contents were measured by
the Bradford method using bovine serum albumin as standard. Each sample was analysed three times by the methods described above.
LPS contamination was tested by Limulus amebocytes lysate (LAL) assay. In brief, 0.1 ml of samples (5 mg/mL), standards or
endotoxin-free water was mixed with 0.1 ml of LAL for 1 h at 37℃ and observed for gelation.
Cells, cell culture and treatment
Mouse hepatoma H22 cells and human hepatoma cell line 7402 were got from Institute of Biochemistry and Cell Biology, Chinese Academy
of Sciences (Shanghai, China). Cells were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v)
Foetus Bovine Serum (Invitrogen, Carlsbad, CA, USA), 100 unit/ml penicillin, 100 unit/ml streptomycin in humidified atmosphere with 5% CO2
at 37oC. Culture medium was daily replaced with fresh medium when cell confluency reached 80~90%. To examine the apoptosis effects induced
by HQG, 7402 cells were treated with HQG at final concentration of 2 µg/mL, 10 µg/mL, 50 µg/mL or 250 µg/mL for 48 h. Afterwards, JC-1
staining and Hochest staining were performed. For JC-1 staining, the stock solution of JC-1 (Invitrogen; Carlsbad, CA, USA) in DMSO (5 mg/ml)
was diluted to 2 μg/ml with RPMI 1640 medium. Then cells were incubated in the dilution JC-1 solution for 30 min. Afterwards, cells were 
rinsed three times with PBS and then were inspected under microscope. For Hochest staining, cells were firstly fixed with methanol/glacial acetic
acid (3:1) for 15 min. After washing twice with PBS, cells were incubated in Hochest staining solution (Invitrogen; Carlsbad, CA, USA) for 5
min at 37℃. After another washing twice with PBS, cells were inspected under microscope.
Mice injection, measurement of tumour weight and cell apoptosis analysis
    Healthy H22 cells were harvested and pre-washed with sterilised PBS three times. One day after inguen hypodermal injection of 100 μl of 
PBS with final cell density of 1 x107/ml to male mice with 5-week age, mice were administered with 0.5 ml of HQG in ddH2O (the content of
HQG was 12.5 mg/kg, 25 mg/kg, 50 mg/kg and 100 mg/kg, respectively). Ten days after administration, mice were sacrificed and the induced
tumour was weighted. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of
Laboratory Animals of Taizhou University (Taizhou, China). The protocol was approved by the Committee on the Ethics of Animal Experiments,
Taizhou University (approval ID: TZ-SKY-010).
    Healthy H22 cells were harvested and pre-washed with sterilised PBS three times. One day after abdomen injection of 500 μl of PBS with 
final cell density of 1 x107/ml to male mice with 5-week age, mice were administered by gavage with 0.5 ml of HQG in ddH2O (the amount of
HQG in ddH2O was mouse weight-dependent, according to the criteria of 50 mg/kg) or only 0.5 ml of ddH2O (as control group). Seven days after
administration, ascites were extracted and cells were prepared from ascites. After three times of washing with PBS, cell apoptosis was analysed
by Annexin V-FITC/PI (Invitrogen, Carlsbad, CA, USA) double staining followed by flow cytometry analysis.
Preparation of mice spleen lymphocytes
Mice with HQG or ddH2O administered (50 mg/kg of HQG in ddH2O) as described previously were sacrificed, and then freshly extracted
mice spleens were incubated in RPMI 1640 medium supplemented with 10% FCS. Spleens were milled on 200-nylon net with sterilised handle of
syringe followed by centrifugation with 500 x g for 15 min. After the supernate was discarded, spleen lymphocytes were resuspended with 5ml of
pH 7.2 Tris-NH4Cl and incubated for 10 min. After washing twice with RPMI 1640 medium, cells were maintained in complete RPMI 1640
medium supplemented with 10% FCS with final cell density of 1 x 107/ml.
Mice spleen lymphocytes staining and CD4+/CD8+ analysis
Blood samples from mice eyeball and prepared mice spleen lymphocytes in Eppendorf tube were centrifuged with 500 x g for 15 min. After
the removal of supernatant, 500 μl of pre-warmed (37℃) 4% paraformaldehyde (Sigma, St. Louis, MO, USA) in PBS was added to each tube to
suspend cells for 5 min at room temperature. 3 ml of ice-cold staining buffer was then added with the incubation for 5 min at 4℃ followed by 200
x g centrifugation for 10 min to remove supernatant. 1 μl of fluorescent-labelled CD4+ or CD8+ antibodies (BD Pharmingen; San Diego, CA,
USA) diluted in 50μl of DPBS was added in each tube with incubation for 30 min in darkness. Afterwards, cells were washed three times with 
DPBS and suspended in 200 μl of PBS for flow cytometry analysis. 
Analysis of IL-4 and IFN-γ in mice spleen lymphocytes 
2 ml of prepared mice spleen lymphocytes in Eppendorf tube were centrifuged with 500 x g for 5 min. After the removal of supernatant, cell
density was adjusted to 1 x 106/ml with RPMI 1640 medium supplemented with 10% FCS, 20 ng/mL of phorbol 12-myristate 13-acetate (PMA)
(Sigma, St. Louis, MO, USA), 500 μg/mL ionomycin (Sigma, St. Louis, MO, USA) and 10 μmol/L monensin (Sigma, St. Louis, MO, USA). 
Cells were then seeded in 24-well plate with 2 ml/well and maintained in humidified atmosphere with 5% CO2 at 37
oC for 4 hrs. Afterwards, cells
were harvested and briefly rinsed once with wash buffer and re-suspended for 15 min at 4oC in wash buffer containing 10% FBS (v/v) by
adjusting cell density to 1 x 106/ml. 500 μl of 37oC pre-warmed 4% paraformaldehyde (Sigma, St. Louis, MO, USA) in PBS was added to each
tube to suspend cells for 5 min at room temperature. 3 ml of ice-cold DPBS was then added with incubation for 5 min at 4oC followed by 200 x g
centrifugation for 10 min to remove supernatant. Cell pellets were suspended in 100 μl of FACS permeable solution for 10 min at room 
temperature to disrupt membrane. Labelled antibodies against intracellular cytokines IL-4 and IFN-γ (BD Pharmingen; San Diego, CA, USA) 
were added in tubes with incubation for 30 min in darkness according to the antibody usage in instruction manual. Finally, cells were pelleted and
suspended in 200 μl of DPBS for flow cytometry analysis. 





The method of HQG preparation was described in Materials and Method. The prepared HQG was examined by infra-red spectrum (Figure 1,
A) and gel permeation chromatography (GPC) (Figure 1, B; Table 1). Apparently, the extracted polysaccharides with molecular weight ~7,000
Da matched well with HQG. The purity of HQG was evaluated by phenol-sulphuric acid method with more than 95% and LAL analysis showed
no LPS contamination in HQG. These results demonstrated that the extracted HQG in house was with high quality and purity. Accordingly, we
used the self-prepared HQG for the following experiments.
Figure 1: Preparation of HQG: The extracted HQG (See Materials and Methods) were analysed by infra-red spectrum (A) and gel permeation
chromatography (B).
Table 1: The parameters of gel permeation chromatography of prepared HQG
Retention Time Mn Mw Mp polydispensity %Area Mz+1 Mz Area
15.342 3780 5525 7132 1.461780 100.00 9004 7331 1958220
HQG treatment inhibits tumour growth
To investigate the anti-tumour effects of HQG, mice were injected with hepatoma H22 cells followed by administering different dose of
HQG by gavage (see Materials and Methods). Tumours induced by H22 cell injection were then extracted and weighed. In the control mice group
without HQG administration, the average weight of induced tumour was 11.3±0.24g. When administering with final content of 12.5 mg/kg HQG,
some tumour cells planted into the mice were restrained, only six mice grew solid tumours, and the average weight of induced tumour was
significantly reduced to 4.15±2.06g (P < 0.05). Apparently, the effects of tumour growth inhibition were with the dose-dependent manner of
HQG administration. The number of the mice with tumour was reduced to 4 in other higher dosage HQG groups. And the average weight of the
tumour declined from 3.24±1.51g (P < 0.05) in response to final content of 25 mg/kg HQG, 2.12±0.98g (P < 0.05) in response to final content of
50 mg/kg HQG till to 2.10±0.79g (P < 0.05) in response to final content of 100 mg/kg HQG (Figure 2; Table 2). According to the effects of
tumour growth inhibition, we then used 50 mg/kg HQG administration for the following experiments.
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Table 2: Average weight of induced tumour in response to HQG administration
HQG 0 mg/kg 12.5 mg/kg 25 mg/kg 50 mg/kg 100 mg/kg
Average weight (g) 11.3±0.24 4.15±2.06 3.24±1.51 2.12±0.98 2.10±0.79
Figure 2: HQG treatment inhibits tumour growth: Tumour-bearing mice were administered with indicated doze of HQG. Ten days after
administration, mice were sacrificed and the induced tumours were extracted and pictured. X axle means the number of tumours formed in
the mice with tumour cell injection. Y axle means the different doze of HQG administration to tumour-bearing mice.
HQG treatment induces cancer cell apoptosis
Tumour cell apoptosis is a universal mechanism to inhibit the growth of solid tumour. To demonstrate whether the inhibited tumour growth
was due to the cell apoptosis induced by HQG administration, hepatoma H22 cells were injected into mice abdomen and then 0.5 ml of HQG
solution (the amount of HQG in solution was mouse weight-dependent, according to the criteria of 50 mg/kg) was administered to mice by
gavage. Cell apoptosis in induced ascites was analysed by Annexin V-FITC/PI (Invitrogen; Carlsbad, CA, USA) double staining followed by
flow cytometry analysis (see Materials and Methods). The results showed that, compared to the control group (2.31±0.62%), HQG administration
markedly increased the cell apoptosis rate to 11.42±1.29 (P < 0.05) (Figure 3, A and B).
To further verify this, cultured human hepatoma 7402 were treated with HQG and then Hoechst 33342 (Invitrogen; Carlsbad, CA, USA)
staining was performed to examine the cell morphology. In control group without HQG treatment, cells kept the normal morphology (Figure 3, C),
while when HQG treatment introduced, typical apoptotic morphology changes were observed (Figure 3, D). The decrease of mitochondrial
membrane potential is a common event in early cell apoptosis stage. To reveal the mechanism by which HQG induced cell apoptosis, with JC-1
staining [11, 12], we next evaluated the changes of mitochondrial membrane potential in 7402 cells without or with HQG treatment. In 7402 cells
without HQG treatment, J-aggregates with red fluorescence were clearly observed (Figure 3, E). However, after HQG treatment, more
J-monomers with green fluorescence was observed, suggesting mitochondrial membrane potential was decreased in response to HQG treatment.
Taken together, these results demonstrated that HQG induced cell apoptosis both in vitro and in vivo.
HQG treatment facilitates immunomodulation in lymphocytes
To evaluate the immunomodulation by HQG in anti-cancer effects, we firstly examined the CD4+ and CD8+ T-lymphocyte subpopulations in
prepared tumour-bearing mice spleen lymphocytes by flow cytometer. Compared with the control tumour-bearing mice group without HQG
administration (Figure 4, A), the treatment with HQG to tumour-bearing mice caused a significant increase in the number of CD4+ T lymphocyte
from 9.66±0.47 to 21.88±1.21 (P < 0.05) and an increase in the number of CD8+ T lymphocyte from 6.11±0.36 to 10.57±1.02 (P < 0.05) (Figure
4, B). By calculating the ratio of CD4+/CD8+ T lymphocytes, we also found that the ratio of CD4+/CD8+ in mice administered with HQG was
significantly higher than that in control mice (Table 3), suggesting HQG treatment effectively facilitated the immunoregulation in tumour-bearing
mice.
Table 3: The average percentage of CD4+ and CD8+ T lymphocytes subpopulation
Without HQG administration With HQG administration
CD4+ 9.53±0.47 21.38±0.51
CD8+ 6.18±0.36 10.07±0.32
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Table 4: The average percentage of cells with IL-4 or IFN-γsecretion 
Normal Without HQG administration With HQG administration
IL-4+ cell 0.03±0.01 0.04±0.01 0.17±0.07
IFN-γ+cell 0.42±0.03 0.93±0.06 1.38±0.19
Figure 3: HQG treatment induces cancer cell apoptosis: Cells from the ascites of tumour-bearing mice without (A) or with (B) HQG
administration were stained by Annexin V-FITC/PI followed by flow cytometry analysis to analyse cell apoptosis. UL represents the
percentage of dead cells; UR represents the percentage of non-active cells; LR represents the percentage of apoptotic cells; LL represents
the percentage of living cells. Human hepadoma 7402 cells were treated with (D, F) or without (C, E) HQG (50 µg/mL) for 48 hrs and then
Hoechst 33342 and JC-1 staining was performed to examine the cell morphology.





Figure 4: HQG treatment facilitates immunomodulation in lymphocytes: Prepared mice spleen lymphocytes from the tumour-bearing mice with
(B) or without (A) HQG administration were fixed, stained with fluorescent-labelled CD4+ or CD8+ antibodies for 30 min followed by flow
cytometry analysis to measure the percentage of CD4+ or CD8+ T-lymphocytes subpopulation. See detailed experimental protocol in
Materials and Methods. UL means the percent of CD8+ cells, equal to the Th1 cells; LR means the percent of CD4+ cells, equal to the Th2
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cells; LL means the CD4- CD8- cells; UR means the CD4+CD8+ cells. Prepared mice spleen lymphocytes from normal mice (C, a),
tumour-bearing mice without (C, b, c) HQG or tumour-bearing mice with HQG administration (C, d, f) were fixed, stained and labelled
antibodies against intracellular cytokines IL-4 and IFN-γ for 30 min followed by flow cytometry analysis to measure the percentage of cells 
secreting IL-4 (C, upper panel) or IFN-γ (C, lower panel). See detailed experimental protocol in Materials and Methods. UL: the
percentage of IL-4+ cells; LR: the percentage of IFN-γ+ cells.
Finally, we assessed the effects of HQG on the secretion of IFN-γ and IL-4 in prepared tumour-bearing mice spleen lymphocytes by flow 
cytometry. As shown in Figure 4C, compared with normal mice (a) and control tumour-bearing mice without HQG administration (b, c), the
treatment with HQG to tumour-bearing mice resulted in significantly increased cell percentage with IFN-γ and IL-4 secretion (d-f, Table 4). 
Collectively, these results demonstrated that HQG treatment enhanced the cellular and humoral immunity to defence H22 injection-induced
tumorigenesis.
Discussion
In cancer therapy, besides the conventional chemotherapy, radiotherapy and surgery, immunotherapy with active compounds in natural
products represents a promising strategy, since this strategy is with much less negative effects on cancer treatment by improving body’s
immune-defence system. Among these active compounds, multiple plant-derived and microorganism-isolated polysaccharides have been
experimented for anti-cancer and immunostimulating activities (Harada et al., 2002; Yoon et al., 2003; Nergard et al., 2004; Nam et al., 2009;
Won et al., 2011).
In this study, we initially isolated polysaccharides from Artemisia apiacea (HQG) and with infra-red spectrum and gel permeation
chromatography, we showed that the isolated HQG was with high purity (>95%). Using hepatoma cells and cancer-bearing mice model, we
comprehensively investigated the impact of HQG on cell apoptosis and mice immunomodulation. We revealed that HQG treatment significantly
induced cell apoptosis and changed the mitochondrial membrane potential. Furthermore, in cancer-bearing mice, HQG administration markedly
reduced the size of solid tumour and decreased the T-lymphocytes subpopulation ratio of CD4+/CD8+; however, IFN-γ and IL-4 secretion was 
increased in spleen lymphocytes. Collectively, these results clearly showed that HQG is with anti-hepatoma activity by inducing cell apoptosis
and stimulating immunomodulation.
In cellular level, tumorigenesis is the disorder of cell proliferation and cell apoptosis, namely unlimited cell proliferation and excessively low
rate of cell apoptosis. In cancer therapy, it is accepted that the inhibition of cancer cell proliferation only delay the progression of tumorigenesis
but cannot eliminate tumour, while the induction of cancer cell apoptosis is the effective strategy to reduce the tumour size or even to eliminate
tumour (Schulze-Bergkamen et al., 2004). Therefore, the screening of reagents which can induce cancer cell apoptosis is with clinical significance.
In this study, after administration with HQG, the induced tumour size in mice was progressively decreased with doze-dependent manner of HQG
administration (Figure 2; Table 2). Cell apoptosis analysis showed that after HQG administration, cell apoptosis rate in ascites of cancer-bearing
mice was elevated (Figure 3, B and D). Accordingly, this observation well shows that the shrinking of the tumour size is possibly due to the
HQG-induced cancer cell apoptosis. Though we did not comprehensively explore the mechanism by which cancer cell apoptosis was induced by
HQG, our immuno-staining experiments suggested that HQG treatment decreased mitochondrial membrane potential (Figure 3F), which at least
partly contributed to the hepatoma cell apoptosis.
Essentially, tumorigenesis is due to the attenuation of body’s immune-defence system, which makes the cancer cells escape attack by the T
cells (Weaver, 2012; Foster et al., 2011). Therefore, the stimulation of immunomodulation by reagents will contribute to the elimination of cancer
cells in cancer immunotherapy (Han et al., 2006). With HQG administration to tumour-bearing mice, we revealed that not only CD4+ and CD8+
T-lymphocytes subpopulation increased (ratio of CD4+/CD8+ increased too), but also the secretion of IFN-γ and IL-4 elevated (Figure 4). The 
results suggested that HQG treatment may bring out two-step effects to mice immunomodulation. Firstly, treatment with HQG to tumour-bearing
mice caused a significant increase of CD4+ and CD8+ T-lymphocytes subpopulation (Table 3). It was documented that CD4+ T cells themselves
can not only attack cancer cells but also can help CD8+ T cells to attack cancer cells (Foster et al., 2011; Sun et al., 2012). Thus, the increased
CD4+ and CD8+ T-lymphocytes subpopulation in response to HQG administration directly enhanced the body’s immune-defence system to
antagonise tumorigenesis. Secondly, since CD4+ T cells or CD8+ T cells secrete multiple cytokines including IFN-γ (Mumberg et al.,1999); 
Vendrell et al., 2011), then upon the increased CD4+ and CD8+ T- lymphocytes subpopulation, the amount of secreted IFN-γ and IL-4 was further 
elevated. Given the facts that the production of IFN-γ and IL-4 stimulates the Th1-mediated immune-response and Th2-mediated 
immune-response respectively, then the increased cell percentage with IFN-γ and IL-4 secretion suggests the differential immunostimulation 
pathway in response to HQG treatment. Altogether, the anti-cancer activity of HQG is possibly from the combinative effects of different
immunomodulatory pathways activated by HQG.
In conclusion, here we demonstrated that HQG exerts anti-hepatoma activity by inducing cancer cell apoptosis and improving the body’s
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